54851-30-8

Basic information

• Product Name: 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-chloroethyl 1-methylethyl ester
• CAS NO: 54851-30-8
• Molecular Formula: C20H23ClN2O6
• Molecular Weight: 422.865
• Mol File: 54851-30-8.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-chloroethyl 1-methylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-chloroethyl 1-methylethyl ester(54851-30-8)
• EPA Substance Registry System: 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-chloroethyl 1-methylethyl ester(54851-30-8)

Safety Data

• Hazardous Substances Data: 54851-30-8(Hazardous Substances Data)

Upstream product

• 54527-68-3 2-chloroethyl acetoacetate 
• 542-08-5 isopropyl acetoacetate 
• 40100-28-5 isopropyl 3-aminocrotonate 
• 62760-10-5 2-chloroethyl 2-(3-nitrobenzyliden)acetoacetate 
• 99-61-6 3-nitro-benzaldehyde 

Downstream Products

• 75130-56-2 2-acetoxyethyl isopropyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate 
• 82219-48-5 O-Demethyl-Nimodipine Oxidized 
• 82219-47-4 (+/-)-O-Demethyl-Nimodipine 

Relevant articles and documents

Asymmetric N-(3,3-diphenylpropyl)aminoalkyl esters of 4-aryl-2,6- dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acids with antihypertensive activity

A series of asymmetric 4-aryl-1,4-dihydropyridine-3,5-dicarboxylates characterized by the presence of a 3,3-diphenylpropylamino moiety in one of the ester groups were synthesized. They exhibited remarkable antihypertensive activity in spontaneously hypertensive rats as well as affinity for the 1,4- dihydropyridines binding site labelled by 3H-nitrendipine in the calcium channel. Introduction of this bulky and lipophilic amine confers to the whole series an elevated level of antihypertensive activity and a long duration of action, a structure-dependent modulation of the activity being found only in the subset characterized by the presence of a branched propylene bridge between the ester and the amino groups. The presence of the amino group is essential for oral activity. Out of this series, compound 9u (Rec 15/2375- lercanidipine) was selected for clinical development and obtained marketing authorization as an antihypertensive in several countries.

Synthesis of new water-soluble dihydropyridine vasodilators

-